Development and psychometric validation of the Nausea/Vomiting Symptom Assessment patient-reported outcome (PRO) instrument for adults with secondary hyperparathyroidism

Journal of Patient-Reported Outcomes

Table 2 Descriptive Statistics for NVSA^© Scores

	N	Mean	Median	SD	% Floor	% Ceiling	% Missing	Test-Retest Reliability^a
Number of Days of Vomiting or Nausea								0.93
Week 1	80	1.98	1.0	2.46	47.4%	10.3%	2.5%
Week 2	71	1.85	1.0	2.35	46.9%	9.4%	9.9%
Week 3	75	1.62	0.0	2.37	56.2%	9.6%	2.7%
Week 4	70	1.63	0.0	2.34	56.9%	7.7%	7.1%
Week 5	69	1.55	0.0	2.49	64.2%	9.0%	2.9%
Week 6	70	1.61	0.0	2.48	55.9%	13.2%	2.9%
Week 7	68	1.51	0.0	2.52	66.7%	10.6%	2.9%
Week 8	71	1.23	0.0	2.15	64.6%	6.2%	8.4%
Number of Episodes of Vomiting								0.61
Week 1	80	0.97	0.0	1.75	69.2%	1.3%	2.5%
Week 2	71	1.42	0.0	3.88	68.8%	1.6%	9.9%
Week 3	75	0.70	0.0	1.89	78.1%	1.4%	2.7%
Week 4	70	0.82	0.0	2.11	78.5%	1.5%	7.1%
Week 5	69	0.54	0.0	1.50	82.1%	1.5%	2.9%
Week 6	70	0.83	0.0	2.12	79.4%	1.5%	2.9%
Week 7	68	0.68	0.0	1.78	80.3%	1.5%	2.9%
Week 8	71	0.57	0.0	2.34	86.2%	1.5%	8.4%
Mean Severity of Nausea								0.94
Week 1	80	0.78	0.1	1.24	50.0%	1.3%	2.5%
Week 2	71	0.80	0.0	1.40	51.6%	1.6%	9.9%
Week 3	75	0.52	0.0	0.95	56.2%	1.4%	2.7%
Week 4	70	0.52	0.0	1.04	58.5%	3.1%	7.1%
Week 5	69	0.51	0.0	1.12	64.2%	1.5%	2.9%
Week 6	70	0.55	0.0	1.25	55.9%	1.5%	2.9%
Week 7	68	0.51	0.0	1.00	66.7%	1.5%	2.9%
Week 8	71	0.38	0.0	0.83	64.6%	1.5%	8.4%

N sample size, SD standard deviation
Floor = percentage of the sample obtaining the lowest possible score (score of 0) (absence of nausea and vomiting)
Ceiling = percentage of the sample obtaining the highest possible score (greatest nausea and vomiting)
^aTest-retest reliability was intraclass correlations between week 1 to week 2